We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Method Separates Oxidized Monoclonal Antibody (MAb) Species
Product News

Method Separates Oxidized Monoclonal Antibody (MAb) Species

Method Separates Oxidized Monoclonal Antibody (MAb) Species
Product News

Method Separates Oxidized Monoclonal Antibody (MAb) Species


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Method Separates Oxidized Monoclonal Antibody (MAb) Species"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Thermo Fisher Scientific has demonstrated that a hydrophobic interaction chromatography (HIC) column, the Thermo Scientific™ ProPac™ HIC-10 column, is suitable for separating low-concentration species of an intentionally oxidized MAb from the native MAb.

The same method can be used to separate the papain fragments from the intentionally oxidized MAb, as well as the papain fragments of the native MAb.

Application Note 1084: Separation of Papain Digests of Oxidized Monoclonal Antibodies details how the ProPac HIC-10 column can be used to resolve antigen-binding fragments (Fab) and nonantigen-binding fragments (Fc) generated by papain digestion, as well as oxidized Fab/Fc from native Fab/Fc.

Many MAbs have been developed as human therapeutics and several others are under development. These MAbs are subject to various post-translational modifications and are susceptible to degradation during storage and delivery.

Due to the potential impact of these modifications to MAb safety and efficacy, it is necessary to fully characterize and monitor MAb heterogeneity.

Other approaches for the characterization and testing of therapeutic antibodies often are not effective for low-level populations of MAb variants, so this new HIC method delivers a much needed solution that is appropriate for stability studies of therapeutic MAbs.

Advertisement